85 related articles for article (PubMed ID: 38686338)
1. Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy.
Guerassimoff L; Ferrere M; Van Herck S; Dehissi S; Nicolas V; De Geest BG; Nicolas J
J Control Release; 2024 May; 369():376-393. PubMed ID: 38554772
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-Lipid Conjugate and ONC201 Combination Therapy Effectively Treats Orthotopic Pancreatic Tumor-Bearing Mice.
Shrestha P; Ghanwatkar Y; Mahto S; Pramanik N; Mahato RI
ACS Appl Mater Interfaces; 2024 May; ():. PubMed ID: 38813771
[TBL] [Abstract][Full Text] [Related]
3. Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma.
Okuno K; Xu C; Pascual-Sabater S; Tokunaga M; Han H; Fillat C; Kinugasa Y; Goel A
Pharmaceuticals (Basel); 2022 Sep; 15(10):. PubMed ID: 36297310
[TBL] [Abstract][Full Text] [Related]
4. Continuous iontronic chemotherapy reduces brain tumor growth in embryonic avian in vivo models.
Handl V; Waldherr L; Arbring Sjöström T; Abrahamsson T; Seitanidou M; Erschen S; Gorischek A; Bernacka-Wojcik I; Saarela H; Tomin T; Honeder SE; Distl J; Huber W; Asslaber M; Birner-Grünberger R; Schäfer U; Berggren M; Schindl R; Patz S; Simon DT; Ghaffari-Tabrizi-Wizsy N
J Control Release; 2024 May; 369():668-683. PubMed ID: 38548064
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Epithelial-Mesenchymal Transition Is a Possible Underlying Mechanism for Inducing Chemoresistance in MIA PaCa-2 Cells against Gemcitabine and Paclitaxel.
Nakamura H; Watanabe M; Takada K; Sato T; Hikage F; Umetsu A; Muramatsu J; Furuhashi M; Ohguro H
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790973
[TBL] [Abstract][Full Text] [Related]
6. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic Cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract][Full Text] [Related]
7. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
8. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
[TBL] [Abstract][Full Text] [Related]
9. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
10. A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
Soni KS; Thomas D; Caffrey T; Mehla K; Lei F; O'Connell KA; Sagar S; Lele SM; Hollingsworth MA; Radhakrishnan P; Bronich TK
J Pharmacol Exp Ther; 2019 Sep; 370(3):894-901. PubMed ID: 30683666
[TBL] [Abstract][Full Text] [Related]
11. Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Karaca M; Dutta R; Ozsoy Y; Mahato RI
Mol Pharm; 2016 Jun; 13(6):1822-32. PubMed ID: 26981724
[TBL] [Abstract][Full Text] [Related]
12. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V; Luo J; Parmar A; Dai WF; Beca JM; Raphael MJ; Isaranuwatchai W; Habbous S; Tadrous M; Earle CC; Biagi JJ; Mittmann N; Arias J; Gavura S; Chan KKW
JNCI Cancer Spectr; 2022 Jul; 6(4):. PubMed ID: 35758620
[TBL] [Abstract][Full Text] [Related]
13. Preparation and use of nanogels as carriers of drugs.
Li C; Obireddy SR; Lai WF
Drug Deliv; 2021 Dec; 28(1):1594-1602. PubMed ID: 34308729
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]